Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?

Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two oth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lupus 1996-08, Vol.5 (4), p.323-327
Hauptverfasser: Rascu, A., Manger, K., Kraetsch, H-G., Kalden, JR, Manger, B.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 327
container_issue 4
container_start_page 323
container_title Lupus
container_volume 5
creator Rascu, A.
Manger, K.
Kraetsch, H-G.
Kalden, JR
Manger, B.
description Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two other patients developed ON several years after discontinuing steroids. One patient developed ON of both humeral and femoral heads within a few months after the diagnosis of SLE. When we compared the cumulative steroid doses taken by our patients with those described in other reports (43 700 mg and 45 300 mg, respectively), our patients received less steroids (38 834 mg). We found no increased fre quency of Raynaud's phenomenon, leukopenia, anti-phospholipid antibodies, or a flare of SLE activity in our patients with ON, factors which have been reported to be associated with ON. Various pathogenic mechanisms, which could lead to ON in SLE patients are discussed.
doi_str_mv 10.1177/096120339600500414
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_745632080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_096120339600500414</sage_id><sourcerecordid>745632080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1644-21e24516cb17c0a3feb6978e4104a83ce1ac152411cf39a990f96ea05ec0f6a13</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMouK5-AU-5ebHuTJumWy8ii_9gYUH0XLLpVLO2SU1aZb-9LfUmeBqY93szvMfYOcIVYpYtIJcYQ5LkEiAFECgO2AxFlkWDEh-y2QhEI3HMTkLYAUCCuZyxj2f6MvTNr_kmdOQsae-CCdxYHvbDpjGa133bB05-371TozoX-nDJB807U0bGlr2mkjvP1URGJbVkS7Idb5Q1FYVOdcbZm1N2VKk60NnvnLPX-7uX1WO03jw8rW7XkUYpRBQjxSJFqbeYaVBJRVuZZ0sSCEItE02oNKaxQNRVkqs8hyqXpCAlDZVUmMzZxXS39e6zH94XjQma6lpZcn0oMpHKJIYlDGQ8kWPq4KkqWm8a5fcFQjEWW_wtdjAtJlNQb1TsXO_tkOY_xw9LK3ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>745632080</pqid></control><display><type>article</type><title>Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?</title><source>Access via SAGE</source><creator>Rascu, A. ; Manger, K. ; Kraetsch, H-G. ; Kalden, JR ; Manger, B.</creator><creatorcontrib>Rascu, A. ; Manger, K. ; Kraetsch, H-G. ; Kalden, JR ; Manger, B.</creatorcontrib><description>Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two other patients developed ON several years after discontinuing steroids. One patient developed ON of both humeral and femoral heads within a few months after the diagnosis of SLE. When we compared the cumulative steroid doses taken by our patients with those described in other reports (43 700 mg and 45 300 mg, respectively), our patients received less steroids (38 834 mg). We found no increased fre quency of Raynaud's phenomenon, leukopenia, anti-phospholipid antibodies, or a flare of SLE activity in our patients with ON, factors which have been reported to be associated with ON. Various pathogenic mechanisms, which could lead to ON in SLE patients are discussed.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/096120339600500414</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><ispartof>Lupus, 1996-08, Vol.5 (4), p.323-327</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1644-21e24516cb17c0a3feb6978e4104a83ce1ac152411cf39a990f96ea05ec0f6a13</citedby><cites>FETCH-LOGICAL-c1644-21e24516cb17c0a3feb6978e4104a83ce1ac152411cf39a990f96ea05ec0f6a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/096120339600500414$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/096120339600500414$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,315,781,785,793,21824,27927,27929,27930,43626,43627</link.rule.ids></links><search><creatorcontrib>Rascu, A.</creatorcontrib><creatorcontrib>Manger, K.</creatorcontrib><creatorcontrib>Kraetsch, H-G.</creatorcontrib><creatorcontrib>Kalden, JR</creatorcontrib><creatorcontrib>Manger, B.</creatorcontrib><title>Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?</title><title>Lupus</title><description>Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two other patients developed ON several years after discontinuing steroids. One patient developed ON of both humeral and femoral heads within a few months after the diagnosis of SLE. When we compared the cumulative steroid doses taken by our patients with those described in other reports (43 700 mg and 45 300 mg, respectively), our patients received less steroids (38 834 mg). We found no increased fre quency of Raynaud's phenomenon, leukopenia, anti-phospholipid antibodies, or a flare of SLE activity in our patients with ON, factors which have been reported to be associated with ON. Various pathogenic mechanisms, which could lead to ON in SLE patients are discussed.</description><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LxDAQxYMouK5-AU-5ebHuTJumWy8ii_9gYUH0XLLpVLO2SU1aZb-9LfUmeBqY93szvMfYOcIVYpYtIJcYQ5LkEiAFECgO2AxFlkWDEh-y2QhEI3HMTkLYAUCCuZyxj2f6MvTNr_kmdOQsae-CCdxYHvbDpjGa133bB05-371TozoX-nDJB807U0bGlr2mkjvP1URGJbVkS7Idb5Q1FYVOdcbZm1N2VKk60NnvnLPX-7uX1WO03jw8rW7XkUYpRBQjxSJFqbeYaVBJRVuZZ0sSCEItE02oNKaxQNRVkqs8hyqXpCAlDZVUmMzZxXS39e6zH94XjQma6lpZcn0oMpHKJIYlDGQ8kWPq4KkqWm8a5fcFQjEWW_wtdjAtJlNQb1TsXO_tkOY_xw9LK3ng</recordid><startdate>199608</startdate><enddate>199608</enddate><creator>Rascu, A.</creator><creator>Manger, K.</creator><creator>Kraetsch, H-G.</creator><creator>Kalden, JR</creator><creator>Manger, B.</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>199608</creationdate><title>Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?</title><author>Rascu, A. ; Manger, K. ; Kraetsch, H-G. ; Kalden, JR ; Manger, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1644-21e24516cb17c0a3feb6978e4104a83ce1ac152411cf39a990f96ea05ec0f6a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rascu, A.</creatorcontrib><creatorcontrib>Manger, K.</creatorcontrib><creatorcontrib>Kraetsch, H-G.</creatorcontrib><creatorcontrib>Kalden, JR</creatorcontrib><creatorcontrib>Manger, B.</creatorcontrib><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rascu, A.</au><au>Manger, K.</au><au>Kraetsch, H-G.</au><au>Kalden, JR</au><au>Manger, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?</atitle><jtitle>Lupus</jtitle><date>1996-08</date><risdate>1996</risdate><volume>5</volume><issue>4</issue><spage>323</spage><epage>327</epage><pages>323-327</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two other patients developed ON several years after discontinuing steroids. One patient developed ON of both humeral and femoral heads within a few months after the diagnosis of SLE. When we compared the cumulative steroid doses taken by our patients with those described in other reports (43 700 mg and 45 300 mg, respectively), our patients received less steroids (38 834 mg). We found no increased fre quency of Raynaud's phenomenon, leukopenia, anti-phospholipid antibodies, or a flare of SLE activity in our patients with ON, factors which have been reported to be associated with ON. Various pathogenic mechanisms, which could lead to ON in SLE patients are discussed.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><doi>10.1177/096120339600500414</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 1996-08, Vol.5 (4), p.323-327
issn 0961-2033
1477-0962
language eng
recordid cdi_proquest_miscellaneous_745632080
source Access via SAGE
title Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T00%3A26%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20:%20Osteonecrosis%20in%20systemic%20lupus%20erythematosus,%20steroid-induced%20or%20a%20lupus-dependent%20manifestation?&rft.jtitle=Lupus&rft.au=Rascu,%20A.&rft.date=1996-08&rft.volume=5&rft.issue=4&rft.spage=323&rft.epage=327&rft.pages=323-327&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/096120339600500414&rft_dat=%3Cproquest_cross%3E745632080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=745632080&rft_id=info:pmid/&rft_sage_id=10.1177_096120339600500414&rfr_iscdi=true